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AbstrACt
Introduction The Community Ageing Research 75+ Study 
(CARE75+) is a longitudinal cohort study collecting an 
extensive range of health, social and economic data, with 
a focus on frailty, independence and quality of life in older 
age. CARE75+ is the irst international experimental frailty 
research cohort designed using Trial within Cohorts (TwiCs) 
methodology, to align applied epidemiological research 
with clinical trial evaluation of interventions to improve the 
health and well-being of older people living with frailty.
Methods and analysis Prospective cohort study using 
a TwiCs design. One thousand community-dwelling 
older people (≥75 years) will be recruited from UK 
general practices. Nursing home residents, those with an 
estimated life expectancy of 3 months or less and people 
receiving palliative care will be excluded. Data collection 
assessments will be face to face in the person’s home at 
baseline, 6 months, 12 months, 24 months and 48 months, 
including assessments of frailty, cognition, mood, health-
related quality of life, comorbidity, medications, resilience, 
loneliness, pain and self-eficacy. A modiied protocol for 
follow-up by telephone or web based will be offered at 
6 months. Consent will be sought for data linkage and 
invitations to additional studies, including intervention 
studies using the TwiCs design. A blood sample biobank 
will be established for future basic science studies.
Ethics and dissemination CARE75+ was approved by 
the NRES Committee Yorkshire and the Humber—Bradford 
Leeds 10 October 2014 (14/YH/1120). Formal written 
consent is sought if an individual is willing to participate 
and has capacity to provide informed consent. Consultee 
assent is sought if an individual lacks capacity. Study 
results will be disseminated in peer-reviewed scientiic 
journals and scientiic conferences. Key study results will 
be summarised and disseminated to all study participants 
via newsletters, local older people’s publications and local 
engagement events. Results will be reported on a bespoke 
CARE75+ website.
trial registration number ISRCTN16588124;Results 
stage
IntroduCtIon
Global ageing demographic projections indi-
cate that there will be two billion people aged 
over 65 worldwide by 2050.1 2 Frailty is an 
especially problematic expression of popula-
tion ageing, with profound implications for 
planning and delivery of health and social 
care services globally. It is a condition char-
acterised by loss of biological reserves, failure 
of homoeostatic mechanisms and increased 
vulnerability to adverse outcomes following 
relatively minor stressor events.3 4 Thus, a mild 
infection, new medication or minor surgery 
can result in a sudden, disproportionate 
change in health status or functional status 
for an older person with frailty, for example, 
a change from independence to dependence, 
a fall, or development of delirium. Frailty is 
also associated with an increased risk of a 
range of adverse outcomes, including future 
disability, admission to hospital, long-term 
care residence and mortality.5 
strengths and limitations of this study
 Ź Community Ageing Research 75+ Study 
(CARE75+)  is a prospective cohort study recruit-
ing older people aged 75 and over, designed using 
Trial within Cohorts (TwiCs) methods, collecting an 
extensive range of demographic, health and socio-
economic data at baseline, 6, 12, 24 and 48 months.
 Ź Our recruitment strategy, including home consent 
visits, home assessments and use of researchers 
with community language skills, is designed to op-
timise the recruitment of older people across the 
frailty spectrum.
 Ź CARE75+ will recruit participants from a variety of 
ethnic backgrounds and those with advanced frailty 
who are often under-represented in research.
 Ź Care home residents are not eligible for the study, 
aligned with the TwiCs design, meaning that indings 
cannot be generalised to this group of especially frail 
older people.
 Ź CARE75+  is a cohort of high strategic relevance, 
which will help shape future UK and international 
health and research policy in ageing and frailty.
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To date, the healthcare response to frailty has been 
predominantly reactive and secondary care based. 
However, there is increasing recognition that frailty should 
be identified and managed as a long-term condition with 
preventative and proactive care models.6–8 Furthermore, 
with the widespread introduction of robustly developed 
tools to detect frailty in primary care such as the elec-
tronic Frailty Index (eFI) based on routinely available 
primary care electronic health record (EHR) data in the 
UK,9 primary care teams can now more readily and reli-
ably identify older people with frailty within their patient 
populations. These novel approaches are providing 
opportunities to develop and deliver services according 
to frailty status rather than chronological age.
Improved management of frailty requires an integrated 
approach spanning primary care, secondary care and 
social services that incorporates consideration of frailty 
transitions and health trajectories. Where possible, inte-
grated care pathways should be developed and imple-
mented based on suitably targeted, evidence-based 
interventions. Although recruitment to ageing and frailty 
observational research studies has historically been rela-
tively high,10 11 recruitment rates to clinical trials of frailty 
interventions have frequently been low.
The Trial within Cohorts (TwiCs) design12 is an inno-
vative research methodology that has the potential to 
enhance participation of older people with frailty in a 
range of studies including clinical trials, and to increase 
the capacity to conduct high quality frailty research.13 
The TwiCs design has several key features including the 
establishment of an observational cohort to both provide 
longitudinal data and function as a recruitment platform 
for multiple trials and other research studies. Each indi-
vidual trial uses random selection of some (not all) partic-
ipants from the cohort; intervention-centred information 
and consent is applied. The process aims to replicate 
the real world of routine healthcare by taking informed 
consent only from those randomised to receive an inter-
vention, as the ongoing cohort study provides a natural 
control group.
MEthods And AnAlysIs
Aim
Our aim is to establish a longitudinal cohort of older 
people to investigate frailty, disability and quality of life 
in older age and to act a recruitment platform for future 
studies (substudies) to enable the development and eval-
uation of interventions to improve outcomes for older 
people.
Patient and public involvement
We have established a Frailty Oversight Group (FOG) as 
a central component of the Community Ageing Research 
75+ Study (CARE75+) study. The FOG comprises a core 
reference group of four key individuals with links to 
local community organisations involved in the support 
of older people living with frailty, and a minority ethnic 
group advocate from the local authority. The FOG plays a 
key role in developing research questions for the cohort, 
including reviewing any proposed data analyses or nested 
studies.
The FOG had close involvement in developing and 
piloting the outcome assessment schedule for the study, 
highlighting the need to include measures that extend 
beyond traditional health domains into areas such as lone-
liness and resilience in later life. The FOG contributed to 
the development of all study materials, including invita-
tion letters and participant information sheets, to ensure 
alignment with the needs of older people. Results are 
disseminated widely to participants, including through 
regular newsletters and an annual celebration event.
design
A multisite, community-based cohort study using a TwiCs 
design.12
Inclusion criteria
Community-dwelling older people aged ≥75 years.
Exclusion criteria
People with terminal cancer, life expectancy of 3 months 
or less and people in receipt of palliative care services will 
be excluded. Care home residents and people living at 
home who are bedbound will be excluded. However, we 
will attempt to follow up people who transition to a care 
home during the course of the study.
Assessments
The CARE75+ assessment includes detailed informa-
tion on the demographic, health and social circum-
stances of participants. An extensive range of measures 
is collected using validated instruments, including assess-
ments of frailty, cognition, mood, health-related quality 
of life, comorbidity, medications, resilience, loneliness 
and self-efficacy (table 1). The selected measures have 
been carefully chosen to ensure that CARE75+ includes 
measures with the necessary validity, reliability and 
responsiveness to enable both applied epidemiological 
investigation and randomised trial evaluation of future 
interventions to improve outcomes.
list of current assessments
 Ź Demographic information (age, sex, ethnicity, marital 
status, living circumstances, housing type, education, 
previous occupation).
 Ź Family networks and informal support (self-report).
 Ź Resource use: general practitioner (GP), hospital and 
outpatient admissions. Use of aids and adaptations 
(self-report).
 Ź Formal care (self-report).
 Ź Smoking habits and alcohol consumption 
(self-report).
 Ź Vision LogMar Vision test14 (Thompson Software 
Solutions).15
 Ź Hearing (the Whispered Voice test).16
 Ź Sleep (self-report).
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 Ź Medication (prescribed) details (name, dose, 
frequency) will be collected from primary care EHR. 
Non-prescribed medication will be self-reported.
 Ź Cognitive function assessed using the Montreal Cogni-
tive Assessment (MoCA),17 a brief cognitive assessment 
instrument. The MoCA assesses different cognitive 
domains: attention and concentration; executive 
function; memory; language; conceptual thinking; 
calculations and orientation. The total possible score 
is 30, with higher scores indicating better cognitive 
function, and a score of ≥26 considered normal.
 Ź Comorbidities data, collected via the primary care 
EHR and by self-report using the Katz comorbidity 
questionnaire.18 This questionnaire asks questions 
on various health conditions requiring a ‘yes’ or ‘no’ 
response.
 Ź General health and health-related quality of life, 
using the RAND Short-Form 36-Item Health Survey 
(SF-36)19 which includes 36 questions spanning 
eight health domains: physical functioning; bodily 
pain; role limitations due to physical health prob-
lems; role limitations due to personal or emotional 
problems; general mental health; social functioning; 
energy/fatigue and general health perceptions. It 
also includes a single item that provides an indica-
tion of perceived change in health. The SF-36 enables 
calculation of Physical Component Summary and 
Mental Component Summary scores, and derivation 
of an overall Health Utility Score, the Short-Form 
Six Dimension score suitable for use in economic 
evaluations.20
 Ź Health-related quality of life using the EuroQol 
Five Dimension Health Questionnaire (five-level 
version) EQ-5D-5L.21 The EQ-5D-5L five dimensions 
are: mobility, self-care, usual activities, pain/discom-
fort and anxiety/depression. Each dimension has 
five levels of severity: no problems, slight problems, 
moderate problems, severe problems and extreme 
problems. The scores for each of the five dimensions 
are combined in a five-digit number representing 
health status that can be converted into a utility index 
(0 for dead, 1 for perfect health and negative values 
for states worse than death) for use in economic 
evaluations.
 Ź Basic activities of daily living (ADL) using the Barthel 
Index (BI).22 The BI assesses functional status on a 
20-point scale by recording ability to complete ten 
basic ADL; bathing, bladder function, bowel func-
tion, dressing, feeding, grooming, mobility, stairs, 
toilet use and transfers. Higher scores indicate greater 
independence.
 Ź Instrumental ADL, measured using the Nottingham 
Extended ADL (NEADL) scale.23 The NEADL 
includes questions on everyday activities in the 
domains of mobility, kitchen, domestic and leisure 
and is scored between 0 and 66, with higher scores 
indicating greater independence.
 Ź Measures of frailty:
 – Research standard 60-item Frailty Index, based on 
the cumulative deficit model of frailty,24 and previ-
ously validated as part of the English Longitudinal 
Study of Ageing.25 The Frailty Index score is cal-
culated an equally weighted proportion of the 
Table 1 Domains and associated measures included 
in Community Ageing Research 75+ Study  assessment 
schedule
Domain Measures
Sociodemographic Age
Gender
Housing type
Room temperature
Education
Occupation
Qualiications
Family information
Formal support
Informal support
Smoking
Alcohol
Anthropometrics Height
Weight
Body mass index
Bioelectric impedance analysis
General health data Blood pressure
Hearing
Vision
Comorbidities
Medications
Falls
Sleep
Frailty English Longitudinal Study of 
Ageing Frailty Index (FI)
Electronic FI
Phenotype model
Clinical Frailty Scale, 7-category 
version
Edmonton Frail Scale
Health-related quality of 
life
Short-Form 36 Item Health 
Questionnaire
EuroQol 5-Dimension Health 
Questionnaire, ive-level version
Cognition Montreal Cognitive Assessment
Activities of daily 
living (ADL)
Barthel Index
Nottingham Extended ADL
Mobility Timed-up-and-go test
Gait speed
Walking aid
Muscle strength Grip strength
Pain Geriatric pain measure
Loneliness De Jong Gierveld Loneliness 
Scale
Depression Geriatric Depression Scale
Resilience Brief Resilience Scale
Self-eficacy General Self-Eficacy Scale
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number of deficits present in an individual relative 
to the total possible.
 – The phenotype model of frailty, based on the five 
physical characteristics as reported in the original 
Cardiovascular Health Study (slow walking speed, 
weight loss, exhaustion, weak grip strength, low en-
ergy expenditure).3 Slow walking speed is assessed 
by a timed 3 m walk and results stratified by height 
and gender using values described in the original 
Cardiovascular Health Study, from which the phe-
notype model was derived.3 Weight loss is deter-
mined by the following question. ‘In the last year, 
have you lost more than 10 pounds unintention-
ally?’ Exhaustion is identified using the following 
questions: ‘How often in the last week do you feel 
that everything you did was an effort?’ and ‘could 
not get going?’. Responses are: rarely or none of 
the time (<1 day)=0; some or a little of the time 
(1–2 days)=1; moderate amount of the time (3–4 
days)=2; most of the time=3. If the participant an-
swers ‘2’ or ‘3’ to either question they meet the 
criterion for exhaustion. Hand grip strength is 
assessed using a Jamar dynamometer and strati-
fied using criteria from the Cardiovascular Health 
Study3 with the mean of three attempts calculated 
for the dominant and non-dominant hand. Low 
activity is assessed using data obtained from the 
Physical Activity domain of the SF-36.19 Those with 
no characteristics are identified as fit, one or two 
characteristics as prefrail and three to five charac-
teristics as frail.
 – The seven category Clinical Frailty Scale (CFS),24 
which is a validated measure of frailty based on 
clinical descriptors and pictographs, designed for 
specialist and non-specialist use in routine clini-
cal practice. The CFS is an ordinal measure, with 
scores ranging from 1 (fit) to 7 (severe frailty).
 – The Edmonton Frail Scale (EFS),26 which is a val-
idated frailty measure designed for specialist and 
non-specialist use that records information on 
nine frailty domains (cognition, general health, 
functional independence, social support, medica-
tion use, nutrition, mood, continence, functional 
performance). The EFS is scored out of a total 
of 17, with higher scores indicating increasing 
frailty.
 – The eFI score,9 based on the cumulative deficit 
model of frailty, including 36 variables recorded 
in the primary care EHR as part of routine care. 
The eFI score is calculated as an equally weight-
ed proportion of the number of deficits present 
in an individual relative to the total possible. The 
eFI enables identification of frailty categories (fit, 
mild frailty, moderate frailty, severe frailty) and is 
obtained directly from the primary care EHR.
 Ź Height weight and body composition: researcher 
assessment using bioimpedance scales (Marsden 
BFA-220P Body fat analyser). Weight loss is obtained 
by self-report at baseline and calculated from previ-
ously recorded weight data at follow-up time points.
 Ź Blood pressure (Life source auto inflation blood pres-
sure monitor): sitting (three times), standing (once).
 Ź Mobility, calculated using the timed-up-and-go test 
(TUGT).27 The TUGT assesses a person's mobility and 
requires both static and dynamic balance. It measures 
the time that a person takes to rise from a chair, walk 
3 m, turn around, walk back to the chair and sit down. 
A person’s usual walking aid is used if needed. People 
completing the test in less than 20 s tend to be inde-
pendently mobile, able to get in and out of a chair 
without assistance and climb stairs. People completing 
the test in 20–29 s demonstrate greater variability in 
mobility, balance and functional ability. Completion 
of the TUGT in 30 s or more identifies people likely 
to require assistance with getting in and out of a chair, 
climbing stairs and leaving the house.
 Ź Pain, measured using the Geriatric Pain Measure 
Short Form.28 This questionnaire includes items of 
pain intensity (current and last 7 days), and dichot-
omous items on how pain is impacting on a person’s 
mobility, ability to accomplish tasks and to sleep. Items 
are combined to derive an overall summary score.
 Ź Loneliness recorded using the 11-item De Jong 
Gierveld Loneliness scale.29 Subcategories of social 
and emotional loneliness are calculated and a total 
score is derived enabling identification of categories: 
not lonely; moderately lonely; severely lonely; very 
severely lonely.
 Ź Resilience, measured using the Brief Resilience 
Scale (BRS).30 The six items in the BRS include five 
response options, enabling calculation of an overall 
score ranging from 1 to 6, with higher scores indi-
cating greater resilience.
 Ź Self-efficacy, measured using the General Self-Effi-
cacy Scale.31 This scale lists 10 items with 4 response 
options enabling generation of a summary score 
ranging from 10 to 40, with higher scores indicating 
greater resilience.
 Ź Low mood, assessed using the Geriatric Depression 
Scale Short-Form with a score of ≥5 indicating an 
abnormal low mood state.32
 Ź Self-reported falls.
 Ź Full blood count (Leeds and Bradford sties only): 
haemoglobin and mean cell volume; red cell (RCC) 
count; mean cell haemoglobin concentration; mean 
cell haemoglobin; RCC distribution width, white cell 
count (including neutrophils, lymphocytes; mono-
cytes; eosinophils; basophils) and platelets.
 Ź Frozen blood aliquots (Leeds and Bradford sites only) 
for future biochemical analysis, including:
 – Routine biochemistry and haematology: renal pro-
file; liver profile; serum albumin; bone profile; glu-
cose; glycosylated haemoglobin; lipid profile; uric 
acid; clotting.
 – Endocrine function: cortisol; thyroid func-
tion; Insulin-like Growth Factor-1 (IGF-1); 
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Dehydroepiandrosterone (DHEAS); testosterone; 
oestradiol; vitamin D; Parathyroid Hormone (PTH); 
neuronal-specific protein.
 – Immune function: highly sensitive C reactive pro-
tein; inflammatory cytokines; rheumatoid factor; 
markers of immunosenescence.
 – Nutritional markers: vitamin A; vitamins B
2
, B
6
, B
12
; 
vitamin C; ferritin; folate; homocysteine.
 – Biomarkers of ageing: DNA repair capacity; telo-
mere length; markers of oxidative stress.
 – Genetic markers: DNA; RNA; plasma.
The CARE75+ data dictionary is available as an appendix 
file (see online supplementary additional file 1).
Assessment schedule
Participants will be assessed at baseline, 6, 12, 24 and 
48 months. Face-to-face assessments will be conducted 
in the participant’s home. The feasibility of a modified, 
telephone-based or web-based assessment protocol will be 
tested at the 6-month time point for participants who are 
willing and able to undertake assessments in the alterna-
tive formats.
The assessment schedule for CARE75+ (baseline, 6, 12, 
24 and 48 months) has been carefully designed to accel-
erate the frailty translational research pathway by aligning 
robust epidemiological investigation with the typical 
follow-up schedule for feasibility and definitive trials of 
interventions.
sample size
The CARE75+ study will generate a comprehensive dataset 
for applied epidemiological research and will act as a 
recruitment platform for additional studies (substudies), 
including qualitative studies as well as randomised 
controlled trials (RCTs) using TwiCs methods. Therefore, 
the initial recruitment target is based on appropriate 
sample size calculations for pilot RCTs of interventions 
to inform the design of future definitive RCTs along-
side applied epidemiological investigation of modifiable 
component of frailty.
Previous observational studies involving older people 
with frailty have identified that between 600 and 1000 
participants are required for reliable estimates of the 
main effects.33 Following an initial pilot phase involving 
200 participants to test recruitment methods and gather 
data on rates of assent to participation in future trials, 
we plan to recruit 1000 participants over a 4-year period. 
Previous observational studies involving the oldest old 
have reported 18-month attrition rates of around 25% due 
to mortality and withdrawal of consent.10 As our cohort 
will include older people with frailty who are at increased 
risk of adverse outcomes, we plan to recruit a minimum 
of 250 participants per year thereafter, to maintain a 
legacy cohort for future clinical trials. Findings from the 
CARE75+ study will inform the design of a future defini-
tive experimental frailty research cohort of sufficient size 
to nest a series of definitive intervention trials targeted at 
a range of potentially modifiable components of frailty, 
including people living with different frailty severity 
grades.
recruitment
We will work with general practices to identify and recruit 
participants in primary care. Following initial piloting of 
recruitment methods in Bradford and Leeds, West York-
shire, we will extend recruitment to other practices in 
England, using the skills and experience of staff within 
the National Institute for Health Research (NIHR) Clin-
ical Research Networks.
The CARE75+ recruitment, consent, assessment and 
follow-up process is summarised in a study flow chart 
(figure 1).
Participant contact
Potential participants will be posted a study invitation 
pack containing a letter of invitation, a user-friendly 
participant information leaflet with photographs of the 
research staff involved in the home visits and a supporting 
letter from their general practice. Potential participants 
who are not interested in participating in the study will 
be invited to contact their general practice to opt out. 
If potential participants do not opt out, contact details 
of eligible participants will be provided to the research 
team via a secure email system. The invitation letter will 
be followed up after 2 weeks with a telephone call from 
a researcher to discuss the study in more detail. If initial 
interest is expressed, the researcher and potential partic-
ipant will arrange a home visit for an in-depth discussion 
of the study, where informed, written consent to partici-
pate will be sought.
The recruitment methods take into account the range 
of physical and cognitive challenges encountered by 
older people. Experience from previous cohort studies 
involving older people with frailty, disability and cogni-
tive impairment has demonstrated that direct telephone 
calls or in-person visits are the only reliable methods of 
finding out whether potential participants are interested 
in participating, and may be preferred because they are 
seen as less of a burden.33 Recruitment procedures will 
ensure that an older person with frailty receives all the 
necessary information to make an informed decision 
about participation. Procedures have been developed in 
close partnership with lay representatives through our 
patient and public involvement FOG,34 established as part 
of the NIHR Collaboration for Leadership in Applied 
Health Research and Care, Yorkshire and Humber (NIHR 
CLAHRC) programme.
Participant consent
Following initial telephone contact, researchers will visit 
participants who express an interest in participation and 
verbally explain the study in detail, including providing a 
comprehensive study information leaflet. Potential partic-
ipants will be able to have an advocate, family member 
or friend present and will be offered 48 hours to reflect 
on the information before deciding to consent. For 
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individuals whose first language is not English, a commu-
nity language speaking researcher will be assigned where 
possible or a suitable advocate identified.
Researchers will assess an individual's capacity to 
consent in accordance with the Mental Capacity Act 
(MCA).35 Formal written consent will be sought if an 
individual is willing to participate and has capacity to 
provide informed consent. The consent form will detail 
all processing and disclosure of the information collected 
including data analysis, data linkage, providing contact 
details to future researchers, and the storage and use of 
blood samples. Some components of the consent will be 
optional (eg, taking and storing blood, consenting to 
be approached about other studies). Written consultee 
Figure 1 Data collected during CARE75+ assessments, including all variable and value names and 
labels. CARE75+, Community Ageing Research 75+ Study.
 o
n
 22 M
arch 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026744 on 7 March 2019. Downloaded from 
7Heaven A, et al. BMJ Open 2019;9:e026744. doi:10.1136/bmjopen-2018-026744
Open access
assent will be sought if individual participants do not have 
capacity to consent. Independent consent to participate 
will be obtained for participation in any future trial.
data collection methods
We plan face-to-face data collection, but we will test the 
feasibility of telephone or web-based modified data collec-
tion procedure for participants who are willing, and able, 
at the 6-month time point.
Prescribed medications, comorbidity data and eFI 
scores will be obtained from general practice EHRs, 
extracted using standardised reporting templates devel-
oped for the SystmOne36 and EMISWeb37 primary care 
EHR systems.
All data will be collected using a bespoke electronic data 
capture application (EDCA), the CARE75+ app devel-
oped and tested by Tigerteam Software. Blood samples 
will be collected at baseline and 12 months from partici-
pants in the Bradford and Leeds sites.
research staff training
Research staff will undertake a bespoke training 
programme, depending on skills and experience, 
including: the MCA35; research with older people; phle-
botomy and safeguarding vulnerable adults. Additionally, 
staff will receive training in completion of the individual 
assessment measures and data entry into the EDCA.
Plans to promote participant retention and complete follow-up
We will seek broad and enduring consent for data linkage 
and use of collected data following withdrawal or death, 
aligned with Medical Research Council guidelines for 
maximising the use of cohort data.38
We will post newsletters to participants at least twice a 
year to provide study updates and encourage continued 
engagement. We will hold annual engagement events, 
where feasible to do so, and promote the study locally via 
affiliated newsletters (eg, Age UK Voice magazine) and 
local forums.
data entry, coding, security and storage
The EDCA will comprise two main components: a Data 
Collection Application (DCA) and Back Office System 
(BOS) containing personal identifiable information. The 
DCA will run on Microsoft Windows platform using an 
encrypted embedded database to temporarily store data. 
The BOS database will be on a Microsoft SQL server 
hosted at Bradford Teaching Hospitals NHS Foundation 
Trust (BTHFT). All data will be captured off-line in the 
community. Data will be uploaded regularly to ensure no 
identifiable data remain on the portable device for longer 
than 48 hours. Named researchers will have access to the 
individual details only while data collection takes place. A 
participant’s details will only be released to one researcher 
at a time via the BOS management system. Access to 
modules and functions of both the DCA and BOS will 
be governed by usernames, passwords and role-specific 
access permissions, to maximise data security.
Remote site data (outside BTHFT) and the on-line 
completion forms (optional 6-month follow-up protocol) 
will be transferred to the BIHR-CARE database via the 
web application  auecr. bradfordhospitals. nhs. uk hosted 
on the web server bhts-bihrweb. The site will be protected 
by SSL certificates, to encrypt the transfer of data over 
the internet. Access to the web application https:// auecr. 
bradfordhospitals. nhs. uk on the server bhts-bihrweb will 
be restricted and protected by the Threat Management 
Gateway software and SSL certificates. Remote site admin-
istrators and researchers will only have access to their own 
local participants.
Access to the BIHR-CARE database information will 
be based on role-specific permissions. The chief inves-
tigator and project manager will have access to all data, 
at all levels for administration and governance purposes. 
Local site administrators will have access to local partic-
ipant details. Researchers will have access to individual 
(site-specific) case information only at the time of data 
collection. Researchers will have a maximum of three 
participants available on portable devices (laptops) at 
any one time. Pathology laboratory staff will have access 
to blood sample data entry pages only. Statisticians and 
other members of the CARE75+ research team will only 
have access to pseudo anonymised, that is, those with 
unique identifiers for use in data linkage or anonymous 
data. Individual participants will be limited to access to a 
blank follow-up questionnaire to complete and submit. 
All submitted data are final and data access is only avail-
able to the Super Administrator at BTHFT.
data quality
Data quality will be enhanced by integral features of the 
data capture software, which will identify missing data and 
outlying values in real time. The software will automati-
cally calculate the total scores for composite assessments. 
This will increase research efficiency and research data 
quality by reducing resource required for data cleansing, 
coding for analysis and reduce inputting errors.
statistical methods
We plan interim data analyses after the completion of 
each stage, that is, baseline, 6, 12, 24 and 48 months 
follow-up of the study. We will assess frailty transitions 
using multivariate statistical methods. We will estimate 
health and social care resource use associated with frailty 
using economic modelling techniques.
We will conduct applied epidemiological investiga-
tion of the association between potentially modifiable 
components of frailty and outcomes, including: how pain 
modifies the association between frailty and disability; 
how resilience modifies the association between frailty 
and disability; and the association between frailty, mood 
and outcomes. We will investigate construct and criterion 
validity of a range of tests collected.39 We will assess frailty 
transitions using transition modelling. We will estimate 
health and social care resource use associated with frailty 
using economic modelling techniques.
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Methods for any additional analyses (subgroup and adjusted 
analyses)
Data will be made available to external investigators on 
request and reviewed by the CARE75+ Data Request 
Review Committee (DRRC), comprising the chief inves-
tigator, CARE75+ project manager, database manager, an 
independent member and independent lay representa-
tive from the FOG.34
The ethnic diversity of our planned recruitment sites 
will enable the investigation of ageing, frailty and disability 
in different cultural contexts.
Missing data
Methods for dealing with missing data will depend on the 
amount of missing data and patterns of missingness for 
individual variables as part of individual analyses. We will 
undertake sensitivity analysis to investigate the impact of 
missing data and we will explore the use of appropriate 
imputation methods.
Ethics and dissemination
CARE75+ is an observational study with low risk to 
participants. Cohort governance will be provided by the 
National Institute for Health Research Collaboration for 
Leadership in Applied Health Research and Care York-
shire and Humber (NIHR CLAHRC YH) Frailty Theme40 
Operational Group comprised the theme leads, theme 
manager, project managers and coapplicants. Inde-
pendent scrutiny will be provided by the FOG,34 which 
comprised lay members with networks into the wider 
community of older people in Bradford. Day-to-day moni-
toring including data quality checks and validations will 
be the responsibility of a dedicated database manager.
Access to data
BTHFT will be the data controller for CARE75+. Data will 
be made available to external researchers in accordance 
with CARE75+ data sharing protocols following review of 
the CARE75+ data dictionary (online supplementary file 
1) and completion of the CARE75+ data request form 
(online supplementary file 2), review by the DRRC and 
completion of a data sharing transfer agreement.
Ancillary and post-study care
We anticipate that some participants may have potentially 
unmet care needs and may wish to discuss these with 
the researcher. We will ensure that researchers are able 
to signpost participants to local statutory and voluntary 
organisations (eg, Age UK), or request a GP referral for 
social services assessment so that appropriate plans can be 
made for ongoing care.
Safeguarding issues identified during the assessment 
visits will be reported to the research project manager 
who will then take advice from the Adult Safeguarding 
Coordinator in the relevant local authorities.
dissemination policy
Study results will be disseminated in peer-reviewed scien-
tific journals and submitted for consideration at local, 
national and international scientific conferences. Key 
study results will be summarised and disseminated to all 
study participants via newsletters, local older people’s 
publication (eg, Voice magazine, Age UK) and local 
engagement events. Results will be reported on a bespoke 
CARE75+ website.
Research outputs using data from the CARE75+ study will 
be required to acknowledge the data source and funder 
using standardised wording. Additionally, studies involving 
participants identified from the cohort (substudies) will 
be required to acknowledge the CARE75+ cohort in all 
reports. The full protocol and participant level dataset 
will be made available to not-for-profit investigators. 
Enquiries should be made to the CARE75+ chief investi-
gator and will be reviewed by the DRRC.
dIsCussIon
CARE75+ will use novel TwiCs methodology to align 
applied epidemiological research into ageing and frailty 
with clinical trials of interventions, potentially acceler-
ating the translational research pathway in this important 
area.
We describe methods to recruit a cohort of older 
people and collect an extensive range of health, social 
and economic outcome data. We plan to collect a 
range of validated measurements of frailty in CARE75+, 
including the eFI, which has been made available to every 
general practice in England through a national imple-
mentation project, facilitating the rapid translation of 
research findings into clinical practice. Our recruitment 
strategy, including home consent visits, home assessments 
and use of researchers with community language skills, 
is designed to optimise the recruitment of older people 
across the frailty spectrum and from a variety of ethnic 
backgrounds, including those with advanced frailty who 
are often under-represented in research. Care home resi-
dents are not eligible for the study, aligned with the TwiCs 
design, meaning that findings cannot be generalised to 
this group of especially frail older people.
Our vision for CARE75+ is a cohort of high strategic 
relevance, which will help shape future UK and interna-
tional health and research policy in ageing and frailty.
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